Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition

Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138- fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138- cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39. See related commentary by Maron and Abdel-Wahab, p. 535.

Authors

Institutions

Publication Details

Journal
Blood Cancer Discovery
Published
2025-08-29
DOI
https://doi.org/10.1158/2643-3230.bcd-24-0340
Citations
1
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
1.77
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition

Shuhei Koide, Taku Kikuchi, Akiho Tsuchiya, Bahityar Rahmutulla et al.
1 citations
Blood Cancer Discovery
Multiple Myeloma Research and Treatments
1.77
article

Identification of a CD138-Negative Therapy-Resistant Subpopulation in Multiple Myeloma with Vulnerability to Splicing Factor Inhibition

Shuhei Koide, Taku Kikuchi, Akiho Tsuchiya, Bahityar Rahmutulla, Masayuki Yamashita, Kiyoshi Yamaguchi, Yoichi Furukawa, Naoki Itokawa, Keisuke Kataoka, Atsushi Iwama, Noriko Doki, Ryoji Ito, Shinichiro Okamoto, Kazumasa Aoyama, Takayuki Shimizu, Yaeko Nakajima‐Takagi, Akihide Yoshimi, Takahiro Kamiya, Satoshi Kaito, Atsushi Kaneda, Motohiko Oshima, Masahiko Ajiro, Nobuhiro Tsukada
article en
1 citations

Abstract

Single-cell RNA sequencing coupled with VDJ-targeted profiling identified distinct therapy-resistant subpopulations within the minor CD138- fraction of multiple myeloma cells. These subpopulations were characterized by increased differential splicing events associated with overexpression of splicing factors from the SR protein family, with CD138- cells showing selective vulnerability to pharmacologic targeting of the splicing factor RBM39. See related commentary by Maron and Abdel-Wahab, p. 535.

Blood Cancer DiscoveryVol. 6(6)
St. Jude Children's Research Hospital (US), Chiba University (JP), Keio University (JP), Central Institute for Experimental Animals (JP), Kyoto University (JP), Tokyo Metropolitan Komagome Hospital (JP), Tokyo Medical Center (JP), Chiba University Hospital (JP), Japanese Red Cross Medical Center (JP), Institute for Advanced Medical Research (US), Tokyo National Hospital (JP), National Cancer Research Institute (GB), The University of Tokyo (JP)
Openalex Percentile: Top 13%
Multiple Myeloma Research and Treatments
1.77
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.